Literature DB >> 6519154

Naloxone protein binding in adult and foetal plasma.

L A Asali, K F Brown.   

Abstract

Binding of naloxone hydrochloride was determined at 37 degrees C, by equilibrium dialysis against 0.067 M phosphate buffer, pH 7.4, in plasma obtained from 18 healthy adults, and 18 samples of umbilical cord venous (foetal) plasma. The percentage free fraction (% free) in plasma was independent of naloxone concentration (9 ng/ml to 2.5 micrograms/ml). Percent free naloxone in adult (means = 54.0) was lower (p less than 0.01) than in foetal (means = 61.5) plasma. In buffered solutions of purified HSA, %free naloxone (means = 68.7) was independent of HSA concentration over the range 3.0 g/dl to 5.5 g/dl. Adult plasma concentrations of alpha 1-acid glycoprotein (alpha 1-AGP) and beta-lipoprotein were higher (p less than 0.01) than foetal concentrations. Furthermore %free naloxone in foetal plasma decreased with the in-vitro addition of purified alpha 1-AGP. It is suggested that qualitative differences in adult and foetal albumin and quantitative differences in plasma levels of alpha 1-AGP and perhaps beta-lipoprotein are responsible for naloxone plasma binding differences between adults and the newborn.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6519154     DOI: 10.1007/bf00549595

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  Differences in the binding of drugs to plasma proteins from newborn and adult man. II.

Authors:  H Kurz; H Michels; H H Stickel
Journal:  Eur J Clin Pharmacol       Date:  1977-07-19       Impact factor: 2.953

2.  Effects of naloxone on pethidine-induced neonatal depression. Part I--Intravenous naloxone.

Authors:  P C Wiener; M I Hogg; M Rosen
Journal:  Br Med J       Date:  1977-07-23

3.  Altered plasma albumin in the newborn infant.

Authors:  S Wallace
Journal:  Br J Clin Pharmacol       Date:  1977-02       Impact factor: 4.335

4.  Opiate antagonists improve survival in anaphylactic shock.

Authors:  S Amir
Journal:  Eur J Pharmacol       Date:  1982-05-07       Impact factor: 4.432

5.  Characteristic properties of fetal human albumin (Alb F) in isomerization equilibrium.

Authors:  K Miyoshi; K Saijo; Y Kotani; T Kashiwagi; H Kawai
Journal:  Tokushima J Exp Med       Date:  1966-11

6.  Meperidine binding in maternal and fetal plasma.

Authors:  R L Nation
Journal:  Clin Pharmacol Ther       Date:  1981-04       Impact factor: 6.875

7.  Differential transplacental binding of diazepam: causes and implications.

Authors:  M J Ridd; K F Brown; R L Nation; C B Collier
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Methadone binding to orosomucoid (alpha 1-acid glycoprotein): determinant of free fraction in plasma.

Authors:  M K Romach; K M Piafsky; J G Abel; V Khouw; E M Sellers
Journal:  Clin Pharmacol Ther       Date:  1981-02       Impact factor: 6.875

9.  Determination of naloxone in blood by high-performance liquid chromatography.

Authors:  L A Asali; R L Nation; K F Brown
Journal:  J Chromatogr       Date:  1983-12-09

10.  Respiratory depression after intrathecal narcotics.

Authors:  G K Davies; C L Tolhurst-Cleaver; T L James
Journal:  Anaesthesia       Date:  1980-11       Impact factor: 6.955

View more
  8 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 2.  The significance of plasma protein binding on the fetal/maternal distribution of drugs at steady-state.

Authors:  M D Hill; F P Abramson
Journal:  Clin Pharmacokinet       Date:  1988-03       Impact factor: 6.447

3.  Differential protein binding of indinavir and saquinavir in matched maternal and umbilical cord plasma.

Authors:  Sreeja Sudhakaran; Craig R Rayner; Jian Li; David C M Kong; Neil M Gude; Roger L Nation
Journal:  Br J Clin Pharmacol       Date:  2006-09-19       Impact factor: 4.335

4.  Protein binding predictions in infants.

Authors:  Patrick J McNamara; Jane Alcorn
Journal:  AAPS PharmSci       Date:  2002

5.  Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women.

Authors:  André Dallmann; Ibrahim Ince; Juri Solodenko; Michaela Meyer; Stefan Willmann; Thomas Eissing; Georg Hempel
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

6.  In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine.

Authors:  Sam Boase; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

7.  Improving Pediatric Protein Binding Estimates: An Evaluation of α1-Acid Glycoprotein Maturation in Healthy and Infected Subjects.

Authors:  Anil R Maharaj; Daniel Gonzalez; Michael Cohen-Wolkowiez; Christoph P Hornik; Andrea N Edginton
Journal:  Clin Pharmacokinet       Date:  2018-05       Impact factor: 5.577

8.  Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block.

Authors:  Phu N Tran; Jiansong Sheng; Aaron L Randolph; Claudia Alvarez Baron; Nicolas Thiebaud; Ming Ren; Min Wu; Lars Johannesen; Donna A Volpe; Dakshesh Patel; Ksenia Blinova; David G Strauss; Wendy W Wu
Journal:  PLoS One       Date:  2020-11-06       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.